Ramos NF

Language: Spanish
References: 60
Page: 20-27
PDF size: 86.91 Kb.

Text Extraction

No abstract

REFERENCES

1. Hart FD, Huskisson EC. Non-steroidal anti-inflammatory drugs. Current status and rational therapeutic use. Drugs 1984; 27: 232-255.

2. Brogden RN. Non-steroidal anti-inflammatory analgesics other than salicilates. Drugs 1986; 32: (Suppl 4) 27-45.

3. Clements PJ, Paulus HE. Nonsteroidal antirheumatic drugs. In: Textbook of Rheumatology. Fifth Edition. Kelly WN, Harris DE, Ruddy S, Sledge CB, Editors. W. B. Saunders Co. Philadelphia 1997: 707-740.

4. Furst DE, Paulus HE. Aspirin and other nonsteroidal antiinflammatory drugs. In: Arthritis and allied conditions. 12th Edition. McCarty DJ & Koopman WJ. Editors. Lea & Febiger. Philadelphia 1993: 567-602.

5. Rainsford KD. Mode of action, uses, and side effects of anti-inflammatory drugs. Advances in Anti-Rheumatic Therapy. Rainsford KD, Ed. CRC Press. Boca Raton 1995: 59-95.

6. Velo GP, Milanino R. Nongastrointestinal adverse reactions to NSAID. J Rheumatol 1990; 17: (Suppl 20) 42-45.

7. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985; 12: 13-20.

8. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985; 12: 347-353.

9. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985; 12: 562-567.

10. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985; 12: 785-790.

11. Ramos Niembro F. Antiinflamatorios no esteroideos (Parte I). Del acidoacetilsalicílico (1899) a los inhibidores selectivos de COX-2 (1999). Rev Mex Reumatol 2000: 15: 142- 159. (Parte II) Rev Mex Reumatol 2000; 15: 170-182.

12. Abramson SB, Weissmann G. The mechanism of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1989; 32: 1-9.

13. Cryer B, Kimmey MB. Gastrointestinal side effects of nonsteroidal antiinflammatory drugs. Am J Med 1998; 105 (1B): 20S-30S.

14. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Arthritis Rheum 1995; 38: 5-18.

15. Allison MC, Howatson AG, Torrance CJ et al. Gastrointestinal damage associated with de use of nonsteroidal antiinflammatory drugs. N Eng J Med 1992; 327: 749-754.

16. Ramos-Niembro F. Gastropatía producida por antiinflamatorios no esteroideos. Una epidemia silenciosa? Rev Universitaria (Mex) (En prensa).

17. Wolfe M, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Eng J Med 1999; 340: 1888-1899.

18. Schoen RT, Vender RJ. Mechanism of nonsteroidal antiinflammatory drug-induced gastric damage. Am J Med 1989; 86: 449-458.

19. Singh G, Ramey DR. NSAID induced gastrointestinal complications: The ARAMIS perspective-1997. J Rheumatol 1998; 25: (Suppl 51) 8-16.

20. Fries J. Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. Scand J Rheumatol 1996; 25: (Suppl 102) 3-8.

21. Douthwaite AH, Lintott GAM. Gastroscopic observations of effect of aspirin and certain other substances on stomach. Lancet 1938; ii: 222-225.

22. Committee on the Safety of Medicines. CSM update: nonsteroidal antiinflammatory drugs and serious gastrointestinal adverse reactions-1. BMJ 1986; 292: 614.

23. Gibson T. Nonsteroidal anti-inflammatory drugs: another look. Br J Rheumatol 1989; 27: 87-90.

24. Gabriel SE, Jaakkimainen RL, Bombardier C. The costeffectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993; 36: 447-459.

25. National Totals for prescriptions of Antiarthritic Drug Therapies in Canada. Montreal: IMS Canada; 1997.

26. Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life treatening complications of peptic ulcerations. Gut 1987; 28: 257-532.

27. Singh G, Ramey DR, Morfeld D et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch Int Med 1996; 156: 1530-1536.

28. Avorn JU, Solomon D, Levin R et al. Epidemiologic analysis of prophylactic drug use and NSAID gastropathy. Arthritis Rheum 1996; 39: (Suppl) S185 (Abstract 827).

29. Tamblyn R, Berkson L, Dauphinee D et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Int Med 1997; 127: 429-438.

30. Langman MJS, Wainwright P, Lawson DH et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-1078.

31. Jaszeweski R. Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or non steroidal antiinflammatory drugs. J Clin Gastroenterol 1990; 12: 10-13.

32. Raskin JB. Gastrointestinal effects of nonsteroidal antiinflammatory therapy. Am J Med 1999; 106 (5B):3S-12S.

33. Labeling revisions for NSAIDs. FDA Drug Bull 1989; 19: 3-4.

34. Paulus HE. FDA Arthritis Advisory Committee Meeting: Post-marketing surveillance of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1985; 28: 1168-1169.

35. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105 (1B) 31S-38S.

36. Rothenberg RJ, Holcomb JP. Guidelines for monitoring NSAIDS. Who listened? J Clin Rheumatol 2000; 5: 258-265.

37. Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999; 26: (Suppl 56) 18-24.

38. Agrawal NM, Roth S, Graham DY et al. Comparison of misoprostol and sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Int Med 1991; 115: 195-200.

39. Ehsanullah RSB, Page MC, Tidesley G et al. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: controlled trial with ranitidine. BMJ 1988; 297: 1017-1021.

40. Taha AS, Hudson N, Hawkey CJ et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Eng J Med 1996; 334: 1435-1439.

41. Walt RP. Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Eng J Med 1992: 327: 1575-1580.

42. Graham DY, White RH, Moreland LW et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Int Med 1993: 119: 257-262.

43. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal antiinflammatory drugs. A randomized double-blind, placebo controlled trial. Ann Int Med 1995; 123: 241-249.

44. Simon LS, Hatoum HT, Bittman RM et al. Risk factors for serious non-steroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996: 28: 202-208.

45. Gabriel SE, Campion ME, O’Fallon M. Patient preferences for nonsteroidal antiinflammatory drug related gastrointestinal complications and their prophylaxis. J Rheumatol 1993; 20: 358-361.

46. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory. Arthritis Rheum 1998; 41: 16-25.

47. Yeomans ND, Zsolt T, Juhász L et al. A comparison of omeprazol with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Eng J Med 1998; 338: 719-726.

48. Hawkey CJ, Karrasch JA, Szczepñski L et al. Omeprazol compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Eng J Med 1998; 338: 727-734.

49. Fu J, Masferrer J, Seibert K et al. The induction and supression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Clin Invest 1990; 86: 1375-79.

50. Xie W, Chipman JG, Robertson DL et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci (USA) 1991; 88: 2692-2696.

51. Simon LS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41: 1591-1602.

52. Emery P, Zeidler H, Kvien TK et al. Celecoxib versus diclofenac in long term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999; 354: 2106-2111.

53. Ehrich EW, Schnitzer T, McIlwain H et al. Effect of specific COX-2 inhibitor in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999; 26: 2438-2447.

54. Goldstein JL, Silverstein F, Agrawal NM et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1679-1690.

55. Hawkey C, Laine L, Simon T et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 2000; 43; 370-377.

56. Alarcón-Ginori A, Barreda-Abascal R. Celecoxib vs Naproxeno, eficacia y tolerabilidad en osteoartrosis. Estudio multicéntrico comparativo, doble ciego aleatorizado. Rev Mex Reumatol 2000; 15: 95-105.

57. Singh G, Ramey DR, Triadafilopoulus G. Early experience with selective COX-2 inhibitors: safety profile in over 340,000 patient years of use. Arthritis Rheum 1999; 42: (Suppl) S296.

58. Silverstein F, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 2000; 284: 1247-1255.

59. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Eng J Med 2000; 343: 1520-1528.

60. Fries J. NSAID Gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18: 6-10.